Sermorelin Tablets: Why Oral and Sublingual Forms Are a Hard Sell

Sermorelin is sold as tablets, capsules and sublingual troches, and two numbers make that a difficult proposition. It is 29 amino acids long, and its half-life is roughly 11 to 12 minutes.

Each of those creates a separate problem for an oral product.

Problem one: length

At 29 residues, sermorelin is a polypeptide rather than a short peptide. That length is a liability in the gut — more residues means more cleavage sites for trypsin, chymotrypsin and brush-border peptidases, and a larger molecule crosses the intestinal wall less readily.

Semaglutide is the instructive comparison. At a similar length, an oral form required co-formulation with a dedicated absorption enhancer, gastric-site absorption, strict dosing conditions and roughly hundredfold dose inflation — plus a full clinical programme. See the oral semaglutide guide.

Problem two: half-life

Sermorelin is cleared in about 11 to 12 minutes. That is extremely short, and it is central to how the compound is supposed to work — a brief pulse triggering a pulse of growth hormone release.

The sublingual argument

Sublingual and buccal delivery bypasses the gut and first-pass hepatic metabolism, which is a genuine advantage. It works well for small, lipophilic molecules — nitroglycerin being the classic example.

• The oral mucosa is thin and well perfused, which is the basis of the approach.

• It is still a barrier to large, hydrophilic molecules, and a 29-residue peptide is both.

• Contact time is limited by swallowing — anything swallowed enters the gut and faces the original problem.

• No published pharmacokinetic data establishes sublingual sermorelin bioavailability in humans.

• No approved sublingual peptide of this size exists, which is informative.

What would demonstrate it works

Sermorelin has a convenient property for testing: its effect is measurable. Unlike compounds with subjective endpoints, a GHRH analogue either provokes growth hormone release or it does not.

1. Serial growth hormone measurements after an oral or sublingual dose.

2. Comparison against the injectable route in the same participants.

3. IGF-1 over weeks, as the downstream marker.

4. A dose-response relationship by the oral route.

None of these studies has been published for oral sermorelin. For contrast, a 2026 phase 3 study of once-weekly somatrogon in adults with growth hormone deficiency shows what a properly measured GH-axis intervention looks like — diagnosed population, randomisation, defined endpoints.

The regulatory position

Sermorelin was approved in the US as Geref and was withdrawn from the market for commercial reasons rather than a safety finding. It is not currently an approved product, and "formerly approved" is routinely shortened to "FDA approved" in marketing.

No oral or sublingual sermorelin product has ever been approved in any form. The approved product was an injection.

If considering an oral product

See the sermorelin dosage guide, sermorelin before and after, the oral peptides guide and the licensed vs certified guide.